CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Reassuring cardiovascular data reported with anti-CGRP therapies

Reassuring safety data have been reported in patients with cardiovascular (CV) disease treated with erenumab or fremanezumab.1-3 In a post-hoc analysis of long-term erenumab data from 2443 patients with episodic or chronic migraine with or without aura, the vascular safety profile was similar in patients with/without a history of aura and was comparable to that …

Read more »

Extensive CONQUER data support galcanezumab in treatment-resistant migraine

Extensive data from the double-blind and open-label phases of the Phase 3 CONQUER study of galcanezumab in treatment-resistant migraine have highlighted the drug’s positive effects on a broad range of outcomes, including monthly migraine headache days (MMHD), >50% responder rates, health-related quality of life, work productivity and inter-ictal burden.1-4 In an analysis of 186/462 (40.3%) …

Read more »

Eptinezumab benefits reported in medication-overuse headache

Eptinezumab reduces migraine days in patients with chronic migraine (CM) and medication-overuse headache (MOH) as early as day 1 of treatment and effects are sustained through 24 weeks of therapy, according to data from the PROMISE-2 study.1 Of 1072 patients with CM who were treated, 431 (40.2%) were diagnosed with MOH. During weeks 1-12, monthly …

Read more »

Generating real world data from patient and physician perspectives

Real world data on the use of erenumab in Germany demonstrate the importance of gaining both the patient and physician perspectives on the impact of treatment. Comparative results from online surveys (PERISCOPE in 90 patients and TELESCOPE in 45 physicians documenting 542 patients) indicate both differences and overlap in experiences of erenumab treatment. In PERISCOPE, …

Read more »

Fremanezumab analysis shows benefits in ≥60s

Fremanezumab was effective and improved quality of life and work productivity in patients ≥60 years of age, according to analyses of pooled data from phase 3 trials in episodic and chronic migraine (HALO EM, HALO CM, and FOCUS).1,2 In 246 patients ≥60, mean monthly migraine days (MMDs) were reduced by 4.3 days with quarterly fremanezumab …

Read more »

microRNAs show biomarker potential in chronic migraine with medication overuse

microRNA expression patterns may have potential as biomarkers for medication overuse (MO) in patients with chronic migraine.1 Results of a study of plasma CGRP levels and microRNA expression patterns before and after detoxification showed that, while changes in CGRP were indicative of migraine severity, microRNA changes were aligned with MO. Dr Chiara Demartini, from the …

Read more »